Topics

Diffuse midline glioma | Treatment | Immunotherapy | Ivonescimab (anti-PD-1/VEGF bispecific antibody)

Home > Publications > Topics > Diffuse midline glioma > Treatment > Immunotherapy > Ivonescimab

Yanchu L, Hongbin W, Xiaoli Y, Li Z, Jun W, Meiling R, Xiaoyan Y, Lei L, Feng W.
Pilot report of an anti-PD-1/VEGF bispecific antibody for treating recurrent H3K27M-mutant diffuse midline gliomas.
Cancer Immunol Immunother. 2026 Jul 14. doi: 10.1007/s00262-026-04434-8. PMID: 42446735. ˍ